ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Ischemic Heart Disease (IHD)Drugs Market Research Report 2025
Published Date: August 2025
|
Report Code: QYRE-Auto-11R11417
Home | Market Reports | Health| Health Conditions| Heart & Hypertension
Global Ischemic Heart Disease IHD Drugs Market Research Report 2022
BUY CHAPTERS

Global Ischemic Heart Disease (IHD)Drugs Market Research Report 2025

Code: QYRE-Auto-11R11417
Report
August 2025
Pages:84
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Astrazeneca plc
Bayer
Eli Lilly
Novartis
Pfizer Inc
Sanofi

Ischemic Heart Disease (IHD)Drugs Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Ischemic Heart Disease (IHD)Drugs Market

Ischemic Heart Disease (IHD)Drugs Market

The global market for Ischemic Heart Disease (IHD)Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Ischemic heart disease (IHD), refers to a group of diseases which includes stable angina, unstable angina, myocardial infarction, and sudden cardiac death. It is within the group of cardiovascular diseases of which it is the most common type. A common symptom is chest pain or discomfort which may travel into the shoulder, arm, back, neck, or jaw.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Ischemic Heart Disease (IHD)Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ischemic Heart Disease (IHD)Drugs.
The Ischemic Heart Disease (IHD)Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Ischemic Heart Disease (IHD)Drugs market comprehensively. Regional market sizes, concerning products by Type, by Sales Channel, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Ischemic Heart Disease (IHD)Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Sales Channel, and by regions.

Scope of Ischemic Heart Disease (IHD)Drugs Market Report

Report Metric Details
Report Name Ischemic Heart Disease (IHD)Drugs Market
CAGR 5%
Segment by Type
  • Antidyslipidemic Drugs
  • Calcium Channel Blockers
  • Beta-blockers
  • ACE Inhibitors
  • Vasodilators
  • Antithrombotic Agents
  • Others
Segment by Sales Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company AstraZeneca, Bayer, Eli Lilly, Novartis, Pfizer, Sanofi
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Ischemic Heart Disease (IHD)Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Ischemic Heart Disease (IHD)Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Sales Channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Ischemic Heart Disease (IHD)Drugs Market report?

Ans: The main players in the Ischemic Heart Disease (IHD)Drugs Market are AstraZeneca, Bayer, Eli Lilly, Novartis, Pfizer, Sanofi

What are the Type segmentation covered in the Ischemic Heart Disease (IHD)Drugs Market report?

Ans: The Types covered in the Ischemic Heart Disease (IHD)Drugs Market report are Antidyslipidemic Drugs, Calcium Channel Blockers, Beta-blockers, ACE Inhibitors, Vasodilators, Antithrombotic Agents, Others

1 Ischemic Heart Disease (IHD)Drugs Market Overview
1.1 Product Definition
1.2 Ischemic Heart Disease (IHD)Drugs by Type
1.2.1 Global Ischemic Heart Disease (IHD)Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Antidyslipidemic Drugs
1.2.3 Calcium Channel Blockers
1.2.4 Beta-blockers
1.2.5 ACE Inhibitors
1.2.6 Vasodilators
1.2.7 Antithrombotic Agents
1.2.8 Others
1.3 Ischemic Heart Disease (IHD)Drugs by Sales Channel
1.3.1 Global Ischemic Heart Disease (IHD)Drugs Market Value by Sales Channel (2024 VS 2031)
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.4 Global Ischemic Heart Disease (IHD)Drugs Market Size Estimates and Forecasts
1.4.1 Global Ischemic Heart Disease (IHD)Drugs Revenue 2020-2031
1.4.2 Global Ischemic Heart Disease (IHD)Drugs Sales 2020-2031
1.4.3 Global Ischemic Heart Disease (IHD)Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Ischemic Heart Disease (IHD)Drugs Market Competition by Manufacturers
2.1 Global Ischemic Heart Disease (IHD)Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Ischemic Heart Disease (IHD)Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Ischemic Heart Disease (IHD)Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Ischemic Heart Disease (IHD)Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Ischemic Heart Disease (IHD)Drugs, Product Type & Application
2.7 Global Key Manufacturers of Ischemic Heart Disease (IHD)Drugs, Date of Enter into This Industry
2.8 Global Ischemic Heart Disease (IHD)Drugs Market Competitive Situation and Trends
2.8.1 Global Ischemic Heart Disease (IHD)Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Ischemic Heart Disease (IHD)Drugs Players Market Share by Revenue
2.8.3 Global Ischemic Heart Disease (IHD)Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Ischemic Heart Disease (IHD)Drugs Market Scenario by Region
3.1 Global Ischemic Heart Disease (IHD)Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Ischemic Heart Disease (IHD)Drugs Sales by Region: 2020-2031
3.2.1 Global Ischemic Heart Disease (IHD)Drugs Sales by Region: 2020-2025
3.2.2 Global Ischemic Heart Disease (IHD)Drugs Sales by Region: 2026-2031
3.3 Global Ischemic Heart Disease (IHD)Drugs Revenue by Region: 2020-2031
3.3.1 Global Ischemic Heart Disease (IHD)Drugs Revenue by Region: 2020-2025
3.3.2 Global Ischemic Heart Disease (IHD)Drugs Revenue by Region: 2026-2031
3.4 North America Ischemic Heart Disease (IHD)Drugs Market Facts & Figures by Country
3.4.1 North America Ischemic Heart Disease (IHD)Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Ischemic Heart Disease (IHD)Drugs Sales by Country (2020-2031)
3.4.3 North America Ischemic Heart Disease (IHD)Drugs Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Ischemic Heart Disease (IHD)Drugs Market Facts & Figures by Country
3.5.1 Europe Ischemic Heart Disease (IHD)Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Ischemic Heart Disease (IHD)Drugs Sales by Country (2020-2031)
3.5.3 Europe Ischemic Heart Disease (IHD)Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Ischemic Heart Disease (IHD)Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Ischemic Heart Disease (IHD)Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Ischemic Heart Disease (IHD)Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Ischemic Heart Disease (IHD)Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Ischemic Heart Disease (IHD)Drugs Market Facts & Figures by Country
3.7.1 Latin America Ischemic Heart Disease (IHD)Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Ischemic Heart Disease (IHD)Drugs Sales by Country (2020-2031)
3.7.3 Latin America Ischemic Heart Disease (IHD)Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Ischemic Heart Disease (IHD)Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Ischemic Heart Disease (IHD)Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Ischemic Heart Disease (IHD)Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Ischemic Heart Disease (IHD)Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Ischemic Heart Disease (IHD)Drugs Sales by Type (2020-2031)
4.1.1 Global Ischemic Heart Disease (IHD)Drugs Sales by Type (2020-2025)
4.1.2 Global Ischemic Heart Disease (IHD)Drugs Sales by Type (2026-2031)
4.1.3 Global Ischemic Heart Disease (IHD)Drugs Sales Market Share by Type (2020-2031)
4.2 Global Ischemic Heart Disease (IHD)Drugs Revenue by Type (2020-2031)
4.2.1 Global Ischemic Heart Disease (IHD)Drugs Revenue by Type (2020-2025)
4.2.2 Global Ischemic Heart Disease (IHD)Drugs Revenue by Type (2026-2031)
4.2.3 Global Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Ischemic Heart Disease (IHD)Drugs Price by Type (2020-2031)
5 Segment by Sales Channel
5.1 Global Ischemic Heart Disease (IHD)Drugs Sales by Sales Channel (2020-2031)
5.1.1 Global Ischemic Heart Disease (IHD)Drugs Sales by Sales Channel (2020-2025)
5.1.2 Global Ischemic Heart Disease (IHD)Drugs Sales by Sales Channel (2026-2031)
5.1.3 Global Ischemic Heart Disease (IHD)Drugs Sales Market Share by Sales Channel (2020-2031)
5.2 Global Ischemic Heart Disease (IHD)Drugs Revenue by Sales Channel (2020-2031)
5.2.1 Global Ischemic Heart Disease (IHD)Drugs Revenue by Sales Channel (2020-2025)
5.2.2 Global Ischemic Heart Disease (IHD)Drugs Revenue by Sales Channel (2026-2031)
5.2.3 Global Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Sales Channel (2020-2031)
5.3 Global Ischemic Heart Disease (IHD)Drugs Price by Sales Channel (2020-2031)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Company Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca Ischemic Heart Disease (IHD)Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 AstraZeneca Ischemic Heart Disease (IHD)Drugs Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 Bayer
6.2.1 Bayer Company Information
6.2.2 Bayer Description and Business Overview
6.2.3 Bayer Ischemic Heart Disease (IHD)Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Bayer Ischemic Heart Disease (IHD)Drugs Product Portfolio
6.2.5 Bayer Recent Developments/Updates
6.3 Eli Lilly
6.3.1 Eli Lilly Company Information
6.3.2 Eli Lilly Description and Business Overview
6.3.3 Eli Lilly Ischemic Heart Disease (IHD)Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Eli Lilly Ischemic Heart Disease (IHD)Drugs Product Portfolio
6.3.5 Eli Lilly Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Company Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Ischemic Heart Disease (IHD)Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Novartis Ischemic Heart Disease (IHD)Drugs Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Company Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Ischemic Heart Disease (IHD)Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Pfizer Ischemic Heart Disease (IHD)Drugs Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 Sanofi
6.6.1 Sanofi Company Information
6.6.2 Sanofi Description and Business Overview
6.6.3 Sanofi Ischemic Heart Disease (IHD)Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Sanofi Ischemic Heart Disease (IHD)Drugs Product Portfolio
6.6.5 Sanofi Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Ischemic Heart Disease (IHD)Drugs Industry Chain Analysis
7.2 Ischemic Heart Disease (IHD)Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Ischemic Heart Disease (IHD)Drugs Production Mode & Process Analysis
7.4 Ischemic Heart Disease (IHD)Drugs Sales and Marketing
7.4.1 Ischemic Heart Disease (IHD)Drugs Sales Channels
7.4.2 Ischemic Heart Disease (IHD)Drugs Distributors
7.5 Ischemic Heart Disease (IHD)Drugs Customer Analysis
8 Ischemic Heart Disease (IHD)Drugs Market Dynamics
8.1 Ischemic Heart Disease (IHD)Drugs Industry Trends
8.2 Ischemic Heart Disease (IHD)Drugs Market Drivers
8.3 Ischemic Heart Disease (IHD)Drugs Market Challenges
8.4 Ischemic Heart Disease (IHD)Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Astrazeneca plc
Bayer
Eli Lilly
Novartis
Pfizer Inc
Sanofi
List of Tables
 Table 1. Global Ischemic Heart Disease (IHD)Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Ischemic Heart Disease (IHD)Drugs Market Value by Sales Channel (2024 VS 2031) & (US$ Million)
 Table 3. Global Ischemic Heart Disease (IHD)Drugs Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Ischemic Heart Disease (IHD)Drugs Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Ischemic Heart Disease (IHD)Drugs Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Ischemic Heart Disease (IHD)Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Ischemic Heart Disease (IHD)Drugs Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Ischemic Heart Disease (IHD)Drugs Average Price (USD/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Ischemic Heart Disease (IHD)Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Ischemic Heart Disease (IHD)Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Ischemic Heart Disease (IHD)Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of Ischemic Heart Disease (IHD)Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Ischemic Heart Disease (IHD)Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ischemic Heart Disease (IHD)Drugs as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Ischemic Heart Disease (IHD)Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Ischemic Heart Disease (IHD)Drugs Sales by Region (2020-2025) & (K Units)
 Table 18. Global Ischemic Heart Disease (IHD)Drugs Sales Market Share by Region (2020-2025)
 Table 19. Global Ischemic Heart Disease (IHD)Drugs Sales by Region (2026-2031) & (K Units)
 Table 20. Global Ischemic Heart Disease (IHD)Drugs Sales Market Share by Region (2026-2031)
 Table 21. Global Ischemic Heart Disease (IHD)Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Region (2020-2025)
 Table 23. Global Ischemic Heart Disease (IHD)Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Region (2026-2031)
 Table 25. North America Ischemic Heart Disease (IHD)Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Ischemic Heart Disease (IHD)Drugs Sales by Country (2020-2025) & (K Units)
 Table 27. North America Ischemic Heart Disease (IHD)Drugs Sales by Country (2026-2031) & (K Units)
 Table 28. North America Ischemic Heart Disease (IHD)Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Ischemic Heart Disease (IHD)Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Ischemic Heart Disease (IHD)Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Ischemic Heart Disease (IHD)Drugs Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Ischemic Heart Disease (IHD)Drugs Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Ischemic Heart Disease (IHD)Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Ischemic Heart Disease (IHD)Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Ischemic Heart Disease (IHD)Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Ischemic Heart Disease (IHD)Drugs Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Ischemic Heart Disease (IHD)Drugs Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Ischemic Heart Disease (IHD)Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Ischemic Heart Disease (IHD)Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Ischemic Heart Disease (IHD)Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Ischemic Heart Disease (IHD)Drugs Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Ischemic Heart Disease (IHD)Drugs Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Ischemic Heart Disease (IHD)Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Ischemic Heart Disease (IHD)Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Ischemic Heart Disease (IHD)Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Ischemic Heart Disease (IHD)Drugs Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Ischemic Heart Disease (IHD)Drugs Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Ischemic Heart Disease (IHD)Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Ischemic Heart Disease (IHD)Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Ischemic Heart Disease (IHD)Drugs Sales (K Units) by Type (2020-2025)
 Table 51. Global Ischemic Heart Disease (IHD)Drugs Sales (K Units) by Type (2026-2031)
 Table 52. Global Ischemic Heart Disease (IHD)Drugs Sales Market Share by Type (2020-2025)
 Table 53. Global Ischemic Heart Disease (IHD)Drugs Sales Market Share by Type (2026-2031)
 Table 54. Global Ischemic Heart Disease (IHD)Drugs Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Ischemic Heart Disease (IHD)Drugs Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Type (2020-2025)
 Table 57. Global Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Type (2026-2031)
 Table 58. Global Ischemic Heart Disease (IHD)Drugs Price (USD/Unit) by Type (2020-2025)
 Table 59. Global Ischemic Heart Disease (IHD)Drugs Price (USD/Unit) by Type (2026-2031)
 Table 60. Global Ischemic Heart Disease (IHD)Drugs Sales (K Units) by Sales Channel (2020-2025)
 Table 61. Global Ischemic Heart Disease (IHD)Drugs Sales (K Units) by Sales Channel (2026-2031)
 Table 62. Global Ischemic Heart Disease (IHD)Drugs Sales Market Share by Sales Channel (2020-2025)
 Table 63. Global Ischemic Heart Disease (IHD)Drugs Sales Market Share by Sales Channel (2026-2031)
 Table 64. Global Ischemic Heart Disease (IHD)Drugs Revenue (US$ Million) by Sales Channel (2020-2025)
 Table 65. Global Ischemic Heart Disease (IHD)Drugs Revenue (US$ Million) by Sales Channel (2026-2031)
 Table 66. Global Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Sales Channel (2020-2025)
 Table 67. Global Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Sales Channel (2026-2031)
 Table 68. Global Ischemic Heart Disease (IHD)Drugs Price (USD/Unit) by Sales Channel (2020-2025)
 Table 69. Global Ischemic Heart Disease (IHD)Drugs Price (USD/Unit) by Sales Channel (2026-2031)
 Table 70. AstraZeneca Company Information
 Table 71. AstraZeneca Description and Business Overview
 Table 72. AstraZeneca Ischemic Heart Disease (IHD)Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 73. AstraZeneca Ischemic Heart Disease (IHD)Drugs Product
 Table 74. AstraZeneca Recent Developments/Updates
 Table 75. Bayer Company Information
 Table 76. Bayer Description and Business Overview
 Table 77. Bayer Ischemic Heart Disease (IHD)Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 78. Bayer Ischemic Heart Disease (IHD)Drugs Product
 Table 79. Bayer Recent Developments/Updates
 Table 80. Eli Lilly Company Information
 Table 81. Eli Lilly Description and Business Overview
 Table 82. Eli Lilly Ischemic Heart Disease (IHD)Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 83. Eli Lilly Ischemic Heart Disease (IHD)Drugs Product
 Table 84. Eli Lilly Recent Developments/Updates
 Table 85. Novartis Company Information
 Table 86. Novartis Description and Business Overview
 Table 87. Novartis Ischemic Heart Disease (IHD)Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 88. Novartis Ischemic Heart Disease (IHD)Drugs Product
 Table 89. Novartis Recent Developments/Updates
 Table 90. Pfizer Company Information
 Table 91. Pfizer Description and Business Overview
 Table 92. Pfizer Ischemic Heart Disease (IHD)Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 93. Pfizer Ischemic Heart Disease (IHD)Drugs Product
 Table 94. Pfizer Recent Developments/Updates
 Table 95. Sanofi Company Information
 Table 96. Sanofi Description and Business Overview
 Table 97. Sanofi Ischemic Heart Disease (IHD)Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 98. Sanofi Ischemic Heart Disease (IHD)Drugs Product
 Table 99. Sanofi Recent Developments/Updates
 Table 100. Key Raw Materials Lists
 Table 101. Raw Materials Key Suppliers Lists
 Table 102. Ischemic Heart Disease (IHD)Drugs Distributors List
 Table 103. Ischemic Heart Disease (IHD)Drugs Customers List
 Table 104. Ischemic Heart Disease (IHD)Drugs Market Trends
 Table 105. Ischemic Heart Disease (IHD)Drugs Market Drivers
 Table 106. Ischemic Heart Disease (IHD)Drugs Market Challenges
 Table 107. Ischemic Heart Disease (IHD)Drugs Market Restraints
 Table 108. Research Programs/Design for This Report
 Table 109. Key Data Information from Secondary Sources
 Table 110. Key Data Information from Primary Sources
 Table 111. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Ischemic Heart Disease (IHD)Drugs
 Figure 2. Global Ischemic Heart Disease (IHD)Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Ischemic Heart Disease (IHD)Drugs Market Share by Type: 2024 & 2031
 Figure 4. Antidyslipidemic Drugs Product Picture
 Figure 5. Calcium Channel Blockers Product Picture
 Figure 6. Beta-blockers Product Picture
 Figure 7. ACE Inhibitors Product Picture
 Figure 8. Vasodilators Product Picture
 Figure 9. Antithrombotic Agents Product Picture
 Figure 10. Others Product Picture
 Figure 11. Global Ischemic Heart Disease (IHD)Drugs Market Value by Sales Channel (2020-2031) & (US$ Million)
 Figure 12. Global Ischemic Heart Disease (IHD)Drugs Market Share by Sales Channel: 2024 & 2031
 Figure 13. Hospital Pharmacy
 Figure 14. Retail Pharmacy
 Figure 15. Online Pharmacy
 Figure 16. Global Ischemic Heart Disease (IHD)Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 17. Global Ischemic Heart Disease (IHD)Drugs Market Size (2020-2031) & (US$ Million)
 Figure 18. Global Ischemic Heart Disease (IHD)Drugs Sales (2020-2031) & (K Units)
 Figure 19. Global Ischemic Heart Disease (IHD)Drugs Average Price (USD/Unit) & (2020-2031)
 Figure 20. Ischemic Heart Disease (IHD)Drugs Report Years Considered
 Figure 21. Ischemic Heart Disease (IHD)Drugs Sales Share by Manufacturers in 2024
 Figure 22. Global Ischemic Heart Disease (IHD)Drugs Revenue Share by Manufacturers in 2024
 Figure 23. Global 5 and 10 Largest Ischemic Heart Disease (IHD)Drugs Players: Market Share by Revenue in Ischemic Heart Disease (IHD)Drugs in 2024
 Figure 24. Ischemic Heart Disease (IHD)Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 25. Global Ischemic Heart Disease (IHD)Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 26. North America Ischemic Heart Disease (IHD)Drugs Sales Market Share by Country (2020-2031)
 Figure 27. North America Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Country (2020-2031)
 Figure 28. U.S. Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Canada Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Europe Ischemic Heart Disease (IHD)Drugs Sales Market Share by Country (2020-2031)
 Figure 31. Europe Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Country (2020-2031)
 Figure 32. Germany Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. France Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. U.K. Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Italy Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Russia Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Asia Pacific Ischemic Heart Disease (IHD)Drugs Sales Market Share by Region (2020-2031)
 Figure 38. Asia Pacific Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Region (2020-2031)
 Figure 39. China Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Japan Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. South Korea Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. India Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Australia Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Taiwan Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Indonesia Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Thailand Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Malaysia Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Philippines Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Latin America Ischemic Heart Disease (IHD)Drugs Sales Market Share by Country (2020-2031)
 Figure 50. Latin America Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Country (2020-2031)
 Figure 51. Mexico Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Brazil Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Argentina Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Middle East and Africa Ischemic Heart Disease (IHD)Drugs Sales Market Share by Country (2020-2031)
 Figure 55. Middle East and Africa Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Country (2020-2031)
 Figure 56. Turkey Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 57. Saudi Arabia Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 58. U.A.E Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 59. Global Sales Market Share of Ischemic Heart Disease (IHD)Drugs by Type (2020-2031)
 Figure 60. Global Revenue Market Share of Ischemic Heart Disease (IHD)Drugs by Type (2020-2031)
 Figure 61. Global Ischemic Heart Disease (IHD)Drugs Price (USD/Unit) by Type (2020-2031)
 Figure 62. Global Sales Market Share of Ischemic Heart Disease (IHD)Drugs by Sales Channel (2020-2031)
 Figure 63. Global Revenue Market Share of Ischemic Heart Disease (IHD)Drugs by Sales Channel (2020-2031)
 Figure 64. Global Ischemic Heart Disease (IHD)Drugs Price (USD/Unit) by Sales Channel (2020-2031)
 Figure 65. Ischemic Heart Disease (IHD)Drugs Value Chain
 Figure 66. Channels of Distribution (Direct Vs Distribution)
 Figure 67. Bottom-up and Top-down Approaches for This Report
 Figure 68. Data Triangulation
 Figure 69. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Coronary Imaging Catheter Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-32P14840
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Point-of-care Troponin Testing Instrument Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22I19939
Wed Nov 19 00:00:00 UTC 2025

Add to Cart

Global Troponin Analyzer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-38W19812
Wed Nov 19 00:00:00 UTC 2025

Add to Cart

Global Anticoagulant Medications Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-39V16824
Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions